EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide

Ryan J Jalleh iD, Mark P Plummer iD, Chinmay S Marathe iD, Mahesh M Umapathysivam iD, Daniel R Quast iD, Christopher K Rayner iD, Karen L Jones iD, Tongzhi Wu iD, Michael Horowitz iD, Michael A Nauck iD

The Journal of Clinical Endocrinology & Metabolism · 18.12.2024 · 110 (1) · 1-15

DOI: 10.1210/clinem/dgae719 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, online erschienen am 17.10.2024. Verfasst von Ryan J Jalleh und 9 weiteren Autor:innen. Beteiligte Einrichtung: Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, SA 5000, Australia. Hauptthemen laut MEDLINE: Gastric Emptying, Diabetes Mellitus, Type 2, Hypoglycemic Agents, Glucagon-Like Peptide-1 Receptor Agonists. Die Arbeit wurde bisher 170-mal zitiert (Crossref) und nennt 124 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Mary Overton postdoctoral fellowship.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Glucagon-like peptide-1 (GLP-1) receptor agonists (RAs) are established therapeutics for type 2 diabetes and obesity. Among other mechanisms, they slow gastric emptying and motility of the small intestine. This helps to limit postprandial glycemic excursions and reduce chylomicron formation and triglyceride absorption. Conversely, motility effects may have detrimental consequences, eg, retained gastric contents at endoscopy or general anesthesia, potentially complicated by pulmonary aspiration or bowel obstruction. Data Acquisition We searched the PubMed database for studies involving GLP-1RA therapy and adverse gastrointestinal/biliary events. Data Synthesis Retained gastric contents at the time of upper gastrointestinal endoscopy are found more frequently with GLP-1 RAs but rarely are associated with pulmonary aspiration. Well-justified recommendations for the periprocedural management of GLP-1RAs (eg, whether to withhold these medications and for how long) are compromised by limited evidence. Important aspects to be considered are (1) their long half-lives, (2) the capacity of GLP-1 receptor agonism to slow gastric emptying even at physiological GLP-1 concentrations, (c) tachyphylaxis observed with prolonged treatment, and (d) the limited effect on gastric emptying in individuals with slow gastric emptying before initiating treatment. Little information is available on the influence of diabetes mellitus itself (ie, in the absence of GLP-1 RA treatment) on retained gastric contents and pulmonary aspiration.

Conclusion

Prolonged fasting periods regarding solid meal components, point-of-care ultrasound examination for retained gastric content, and the use of prokinetic medications like erythromycin may prove helpful and represent an important area needing further study to increase patient safety for those treated with GLP-1 RAs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gastric EmptyingDiabetes Mellitus, Type 2Hypoglycemic AgentsGlucagon-Like Peptide-1 Receptor AgonistsHumansGastroparesisGlucagon-Like Peptide-2 ReceptorGastric Inhibitory PolypeptideTirzepatide

Stichwörter der Autor:innen

GLP-1 receptor agonistsGLP-1/GIP dual receptor agonistsaspirationgastric emptyingincretin mimeticsretained gastric contenttachyphylaxis

Substanzen

TirzepatideHypoglycemic AgentsGlucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide-2 ReceptorGastric Inhibitory Polypeptide

Autor:innen und Institutionen

  • Endocrine and Metabolic Unit, Royal Adelaide Hospital, Adelaide, SA 5000, Australia.
  • Adelaide Medical School, The University of Adelaide, Adelaide, SA 5000, Australia.
  • Intensive Care Unit, Royal Adelaide Hospital, Adelaide, SA 5000, Australia.
  • Southern Adelaide Diabetes and Endocrine Service, Flinders Medical Centre, Bedford Park, SA 5042, Australia.
  • Diabetes, Endocrinology, Metabolism Section, Medical Department I, Katholisches Klinikum Bochum gGmbH, Sankt Josef-Hospital, Ruhr-University, D-44791 Bochum, Germany.
  • Department of Gastroenterology and Hepatology, Royal Adelaide Hospital, Adelaide, SA 5000, Australia.

ORCID-Profile: Ryan J Jalleh, Mark P Plummer, Chinmay S Marathe, Mahesh M Umapathysivam, Daniel R Quast, Christopher K Rayner, Karen L Jones, Tongzhi Wu, Michael Horowitz, Michael A Nauck

Förderung

  • Mary Overton postdoctoral fellowship

Zitieren

APA

Jalleh, R. J., Plummer, M. P., Marathe, C. S., Umapathysivam, M. M., Quast, D. R., Rayner, C. K., Jones, K. L., Wu, T., Horowitz, M., & Nauck, M. A. (2024). Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide. The Journal of Clinical Endocrinology & Metabolism, 110(1), 1-15. https://doi.org/10.1210/clinem/dgae719

Vancouver

Jalleh RJ, Plummer MP, Marathe CS, Umapathysivam MM, Quast DR, Rayner CK, et al. Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide. The Journal of Clinical Endocrinology & Metabolism. 2024;110(1):1-15. doi:10.1210/clinem/dgae719

BibTeX
@article{Jalleh2024,
  author = {Jalleh, Ryan J and Plummer, Mark P and Marathe, Chinmay S and Umapathysivam, Mahesh M and Quast, Daniel R and Rayner, Christopher K and Jones, Karen L and Wu, Tongzhi and Horowitz, Michael and Nauck, Michael A},
  title = {Clinical Consequences of Delayed Gastric Emptying With GLP-1 Receptor Agonists and Tirzepatide},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2024},
  volume = {110},
  number = {1},
  pages = {1--15},
  doi = {10.1210/clinem/dgae719}
}
Kostenlos starten →